NVO Jan 2025 80.000 put
| Previous close | 5.53 |
| Open | 5.53 |
| Bid | 5.80 |
| Ask | 6.40 |
| Strike | 80.00 |
| Expiry date | 2025-01-17 |
| Day's range | 5.53 - 5.53 |
| Contract range | N/A |
| Volume | |
| Open interest | 275 |
BloombergObesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
(Bloomberg) -- The global market for novel weight-loss drugs like Novo Nordisk A/S’s Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications.Most Read from BloombergChinese Gold Buying Is Driving a Paradigm Shift in BullionWells Fargo Preps for Wealth Battle After $1 Billion TurnaroundUS to Keep a Distance From India-Canada Dispute, Signum’s Myers SaysBond Market Faces Quandary After Fed Signals It’s Almost DoneRaw Meat-Eating Li
- Investing.com
Global Weight-Loss Drug Market Projected to Hit $100 Billion by 2035
In a recent forecast, BMO Capital Markets has predicted the global market for innovative weight-loss drugs, such as Novo Nordisk (NYSE:NVO) A/S's Ozempic and Wegovy, to reach $100 billion by 2035. This projection follows an increase in patient recognition of the efficacy of these medications.
Motley FoolWhere Will Novo Nordisk Stock Be in 5 Years?
Weight-loss treatments are a big part of Novo Nordisk's business and could be key to its growth for years to come.
